PT  - JOURNAL ARTICLE
AU  - Kornelius, Edy
AU  - Lo, Shih-Chang
AU  - Huang, Chien-Ning
AU  - Wang, Chi-Chih
AU  - Wang, Yu-Hsun
AU  - Yang, Yi-Sun
TI  - Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study
AID  - 10.1136/bmjopen-2024-090428
DP  - 2025 Feb 01
TA  - BMJ Open
PG  - e090428
VI  - 15
IP  - 2
4099  - http://bmjopen.bmj.com/content/15/2/e090428.short
4100  - http://bmjopen.bmj.com/content/15/2/e090428.full
SO  - BMJ Open2025 Feb 01; 15
AB  - Objectives Herpes zoster (HZ) infection is associated with a higher risk of major adverse cardiovascular events (MACE), including stroke and coronary artery disease (CAD). Patients with diabetes are at an increased risk of MACE, highlighting the importance of studying this population to assess the potential protective effects of HZ vaccination. This study aims to investigate the risk of MACE after HZ vaccination in patients with diabetes.Design Retrospective cohort study.Setting Community-based population in the USA.Participants Using the TriNetX database, the study included 4.9 million patients with diabetes from 2006 to 2022. It established two cohorts: 68 178 patients in the HZ vaccination (comprising any HZ vaccine, Shingrix or Zostavax) and 4 835 246 patients in the no HZ vaccination group. After excluding patients with a history of MACE, immune disease and complications of HZ prior to the index date, the study cohort was reduced to 45 960 patients. Propensity score matching, accounting for age, sex, race, socio-economic status and disease comorbidities, was conducted to minimise study bias.Interventions HZ vaccination.Outcome measures MACE outcomes are defined as the first occurrence of CAD or stroke. Comparative risk analysis was conducted using HRs.Results Post matching, the mean patient age was 63.5 years, with 49.2% females. The incidence rate of MACE was lower among vaccinated patients compared with unvaccinated individuals, with an HR of 0.76 (0.72–0.79). For secondary endpoints, the HRs were 0.73 (0.69–0.78) for CAD, 0.79 (0.74–0.84) for stroke and 0.54 (0.52–0.57) for all-cause mortality. These protective effects remained consistent across different age groups, sexes and diabetes types, supporting the potential benefit of HZ vaccination in reducing cardiovascular risk.Conclusions HZ vaccination is associated with a lower risk of MACE in patients with diabetes. Further prospective studies are critically needed to confirm this finding.Data are available upon reasonable request.